Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

In addition to TD Cowen, Biohaven Ltd. also received a Buy from William Blair’s Myles Minter in a report issued today. However, yesterday, RBC Capital maintained a Hold rating on Biohaven Ltd. (NYSE: ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

Morgan Stanley analyst Terence Flynn reiterated a Buy rating on Biohaven Ltd. ( BHVN – Research Report) today and set a price target of $63.00. The company’s shares opened today at $15.43.

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to ...

Biohaven (NYSE:BHVN) shares traded higher on Wednesday after the company said its antibody-drug conjugate BHV-1510 with cemiplimab, an anti-PD-1 therapy marketed by Regeneron (NASDAQ:REGN ...